A study by British specialists indicates that people with complete vaccination schedules are less likely to develop prolonged or persistent COVID.
The analysis, conducted by experts from the UK Health Security Agency (UKHSA)looked at the prevalence of symptoms associated with persistent COVID-19 (also known as “long COVID”) in people who had been vaccinated and in people who were not immunized.
The experts reviewed four studies; of these, three indicated that people with complete vaccination schedules had fewer symptoms associated with persistent COVID compared to those who were not inoculated.
Therefore, the study concluded that people vaccinated with the full schedule of biologics from Pfizer-BioNTech, AstraZeneca or Moderna, or who have received two injections of the Johnson & Johnson vaccine, have approximately half the chance of developing persistent COVID.
“The study shows additional benefits of receiving a full COVID-19 vaccine schedule,” said Mary Ramsay, Head of Immunization at UKHSA.
Persistent COVID or prolonged COVID refers to a series of symptoms that last for several months and are associated with a SARS-CoV-2 infection.
Some of the symptoms of these conditions are fatigue, shortness of breath, as well as muscle or joint pain.
Because more than 400 million people have been infected with COVID-19, the World Health Organization (WHO) has recognized persistent COVID as a disease. According to the organism, the symptoms of this condition generally last for a period of three months after the onset of the disease.